Gene therapy restores hearing to children with inherited deafness
Gene therapy using adeno-associated viruses to deliver a working copy of the OTOF gene has restored significant hearing to children born with a specific form of inherited deafness, prompting both excitement and questions about what such interventions make possible. Commenters explore technical aspects of viral gene delivery, potential future applications ranging from curing other diseases to speculative body modifications, and the limits imposed by physics and biology. Ethical debates surface around heritable changes, access and cost, eugenics fears, and tensions with Deaf culture over whether deafness should be treated as a defect to be “fixed,” especially in children.
Overall reaction
- Many express awe at gene therapy that restores hearing in children and see it as “real” breakthrough tech, not just software.
- Some share personal connections (family genetic hearing loss, ALS, screened embryos) and see this as concrete hope for current or future children.
How the therapy works (as discussed)
- Participants describe AAV vectors delivering a working OTOF gene into inner-ear cells.
- One explanation (later corrected) claimed AAV integrates into chromosomes; follow‑ups clarify AAV usually forms episomes (extra-chromosomal circles), which is why it’s considered safer.
- Clarifications on permanence: integrated DNA is inherited by daughter cells; episomes are long‑lasting but not germline edits.
Prospects and limits of gene editing
- Enthusiasm for “gene CAD” tools, CRISPR design assistants, and existing bio-CAD software (metabolic modeling, plasmid design, generative protein design).
- Some fantasize about radical body redesign (wings, species transition, new senses), while others argue physics, development, metabolism, and pain make such metamorphosis near-impossible or non-human in outcome.
- Discussion of whole-body, permanent editing notes major current obstacles: delivery vectors, organ targeting, toxicity, gene size limits, blood–brain barrier.
Deafness, disability, and ethics
- Debate over whether deafness is a “defect” to be fixed versus a valid identity and culture.
- Strong disagreement about parents declining interventions (e.g., cochlear implants) for children; some call it akin to child abuse, others stress procedure risks and consent.
- Comparisons drawn to LGBTQ identity and to left-handedness; participants argue over what counts as “objective disadvantage.”
Inheritance, IVF, and eugenics worries
- Concern that treated individuals can still pass on recessive deafness alleles; others note autosomal recessive risk is limited and IVF with preimplantation genetic testing can reduce such disorders.
- Some fear slippery slopes to eugenics; others argue selective embryo implantation already does “screening.”
Access, patents, and incentives
- Disagreement on patents and “rent-seeking”: some want Salk-style open sharing; others argue incentives are needed but current IP systems encourage monopoly and lobbying.
- Worries about dependence on expensive corporate therapies versus calls for better healthcare systems and broader funding.